Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 10:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vaccine Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above

NCT06374394
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccine, COVID-19 mRNA vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
841 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
8
States / cities
Coral Gables, Florida • Savannah, Georgia • Evansville, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Sep 22, 2026, 10:31 AM EDT
Recruiting Phase 1Phase 2 Interventional

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

NCT05950139
View directory record Official record
Conditions
NSCLC Stage IV, ALK Fusion Protein Expression
Interventions
Peptide vaccine
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 22, 2026, 10:31 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access Neoantigen Vaccine in Solid Tumors

NCT03914872
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
Neoantigen DNA Vaccine, Integrated electroporation device
Biological · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 22, 2026, 10:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z)

NCT03583606
View directory record Official record
Conditions
Ebola Disease, Immunisation
Interventions
ChAd3-EBO-Z, MVA Multi-Filo Ebola Vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Sep 22, 2026, 10:31 AM EDT
Completed Not applicable Interventional Results available

Does Framing and Humor Improve the Effectiveness of Messages About COVID-19 Vaccine

NCT05085613
View directory record Official record
Conditions
Beliefs
Interventions
Corrective message framing and humor
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
21 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 22, 2026, 10:31 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Stories to Prevent (StoP) HPV Cancers

NCT06808776
View directory record Official record
Conditions
Human Papillomavirus Vaccination, Emotions
Interventions
Cancer survivor narrative, Healthy eating tips
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 22, 2026, 10:31 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Effect of Influenza Vaccination on IVF Outcomes - IVF

NCT02947217
View directory record Official record
Conditions
Infertility
Interventions
Influenza Vaccine, Sterile Saline
Biological · Other
Lead sponsor
Center for Human Reproduction
Other
Eligibility
21 Years to 38 Years · Female only
Enrollment
238 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Sep 22, 2026, 10:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy Adults

NCT02021968
View directory record Official record
Conditions
Dengue
Interventions
TetraVax-DV-TV003, rDEN2∆30-7169, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Sep 22, 2026, 10:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza

NCT01175122
View directory record Official record
Conditions
Influenza A Virus Infection
Interventions
H2N3 MO 2003/AA ca Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 42 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Sep 22, 2026, 10:31 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)

NCT01959945
View directory record Official record
Conditions
Influenza
Interventions
Flublok® Quadrivalent Influenza Virus Vaccine, Fluarix Quadrivalent® Influenza Virus Vaccine
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
6 Years to 17 Years
Enrollment
219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Auburn, Maine
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 22, 2026, 10:31 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immune Response to Shingles Vaccination

NCT02624375
View directory record Official record
Conditions
Shingles
Interventions
Zoster Vaccine Live
Drug
Lead sponsor
University of Washington
Other
Eligibility
70 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Sep 22, 2026, 10:31 AM EDT
Active, not recruiting No phase listed Observational

A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza

NCT05160636
View directory record Official record
Conditions
COVID-19, Coronavirus Disease 2019, Influenza
Interventions
COVID-19 Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 22, 2026, 10:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Active You: Walk, Dance, and Tone Your Abs to Reduce Your Risk of Diabetes

NCT06127251
View directory record Official record
Conditions
Obesity
Interventions
PATH Intervention, Control Group, Physical activity tracker, Dietary education
Behavioral · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 22, 2026, 10:31 AM EDT
Completed Not applicable Interventional Results available

Development and Testing of ADEPT: A Parent Decision Support for Childhood Vaccinations

NCT04496453
View directory record Official record
Conditions
Vaccine Refusal
Interventions
Childhood vaccination decision support tool
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 22, 2026, 10:31 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)

NCT00928577
View directory record Official record
Conditions
Smallpox
Interventions
Not listed
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
17 Years and older
Enrollment
14,108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
4
States / cities
Twentynine Palms, California • Fort Campbell North, Kentucky • Fort Bliss, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Sep 22, 2026, 10:31 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease

NCT05842967
View directory record Official record
Conditions
RESPIRATORY SYNCYTIAL VIRUS (RSV)
Interventions
RSVpreF, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
36
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Sep 22, 2026, 10:31 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination

NCT07425392
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
31-valent pneumococcal conjugate vaccine, PCV20
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
50 Years and older
Enrollment
752 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
30
States / cities
Chinle, Arizona • Phoenix, Arizona • Whiteriver, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 22, 2026, 10:31 AM EDT
Recruiting Phase 1Phase 2 Interventional

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

NCT07288112
View directory record Official record
Conditions
Refractory Melanoma
Interventions
DOC1021, Tumor resection, pIFN (peginterferon alfa-2a)
Biological · Procedure · Drug
Lead sponsor
Diakonos Oncology Corporation
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
8
States / cities
Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 22, 2026, 10:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Messaging Strategies to Increase Peer Education on COVID-19 Vaccination and Climate Change

NCT05530044
View directory record Official record
Conditions
Vaccine Hesitancy, Climate Change
Interventions
Social diffusion intervention
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Sep 22, 2026, 10:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of a Potential Preventive Vaccine Against HIV in Healthy Volunteers

NCT00545987
View directory record Official record
Conditions
HIV Infections
Interventions
TriGrid™ Delivery System, conventional intramuscular injection
Device
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2011 · Synced Sep 22, 2026, 10:31 AM EDT
Completed Phase 2 Interventional Results available

Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma

NCT01290692
View directory record Official record
Conditions
Grade IV Glioma, Grade IV Astrocytoma, Glioblastoma Multiforme
Interventions
TVI-Brain-1
Biological
Lead sponsor
TVAX Biomedical
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
Kansas City, Missouri • St Louis, Missouri • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 22, 2026, 10:31 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine

NCT02270944
View directory record Official record
Conditions
Infections, Streptococcal, Streptococcal Infections
Interventions
GBS Vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
1,053 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
5
States / cities
Redding, California • Lenexa, Kansas • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Sep 22, 2026, 10:31 AM EDT
Completed Phase 1 Interventional

A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant

NCT00001439
View directory record Official record
Conditions
Melanoma
Interventions
gp100 human melanoma peptide
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 22, 2026, 10:31 AM EDT
Completed Phase 1 Interventional

A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects

NCT00002353
View directory record Official record
Conditions
HIV Infections
Interventions
P3C541b Lipopeptide
Biological
Lead sponsor
United Biomedical
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 22, 2026, 10:31 AM EDT